Prollenium, a technology-driven innovator transforming the medical aesthetics industry, announced a new strategic direction. Renowned for developing the category-shifting dermal filler brand, Revanesse, Prollenium is doubling down on their mission to leverage advanced tech infrastructure, vertically integrated manufacturing and an in-house R&D incubator to innovate the next generation of products. The company is now focused on advancements in the future of skin regeneration products and technology.
With extensive expertise and significant investments in multi-disciplinary science and R&D, Prollenium aims to set new standards in skin health through advanced reparative technologies. The upcoming product line will highlight breakthroughs in PDRN (polydeoxyribonucleotide) science, exosome-based therapies, and collagen-stimulating biostimulants, all designed to rejuvenate and repair skin at the cellular level.
“Prollenium has always prioritized creating products that work with the body’s natural processes to enhance outcomes,” stated Ario Khoshbin, Founder and CEO of Prollenium. “This new chapter builds on that foundation, focusing on breakthroughs in PDRN, exosomes, and skin regeneration that will redefine possibilities for practitioners and patients.”
Prollenium’s new objectives center on cellular repair and reprogramming. Its next-generation products are designed to address the root causes of skin aging through advanced compounds and biostimulants, supporting long-term skin health, elasticity, and regeneration.
Key benefits include:
- Science-driven formulations utilizing cutting-edge regenerative medicine.
- Targeted skin repair through exosomes and reparative compounds.
- Collagen enhancement via biostimulants for durable results.
“We are moving beyond traditional aesthetic corrections toward true skin health and longevity,” added Khoshbin. “These innovations equip clinicians to achieve unprecedented outcomes.”
Prollenium’s reputation is built on driving progress in the multi-billion-dollar medical aesthetics market. As the first North American manufacturer of dermal fillers, it has empowered practitioners with high-performing, predictable products with the highest safety profile and lowest inflammation rates on the market. The company’s expansion into skin regeneration reinforces its mission to transform the industry and deliver solutions that address both cosmetic and core health needs.
Aligned with this evolution, Prollenium is enhancing its PACE Academy (Prollenium Advanced Clinical Education), offering specialized training programs to help medical professionals adopt next-generation technologies while maintaining safety and efficacy standards.
